Transient ischemia-induced changes of interleukin-2 and its receptor beta immunoreactivity and levels in the gerbil hippocampal CA1 region.
Interlukin-2 (IL-2) is an important cytokine in the brain: IL-2 and its receptors are involved with inflammatory processes. Chronological changes in IL-2 level in serum, and IL-2 and its receptor (IL-2 receptor beta, IL-2Rbeta) immunoreactivities and levels were examined in the hippocampal CA1 region after transient forebrain ischemia in gerbils. IL-2 level in serum significantly decreased 12 h after ischemia/reperfusion. IL-2 immunoreactivity was detected in the somata of pyramidal cells in sham-operated group. At 15 min after ischemia, IL-2 immunoreactivity was shown in non-pyramidal cells as well as pyramidal cells. One day after ischemia, IL-2 immunoreactivity was lowest, and IL-2 immunoreactivity is shown in non-pyramidal cells from 2 days after ischemia. Four days after ischemia, IL-2 immunoreactivity was shown in dying pyramidal cells. IL-2Rbeta immunoreactivity in the sham-operated and 15 min-3 min post-ischemic groups is detected in the cell membrane of pyramidal cells. From 3 h after ischemia, IL-2Rbeta immunoreactivity is found in cytoplasm and nuclei, but not in cell membrane. IL-2Rbeta immunoreactivity decreases from 6 h after ischemia and is shown mainly in non-pyramidal cells from 3 days after ischemia. The data of Western blot analyses for IL-2 and IL-2Rbeta was similar to the immunohistochemical data. IL-2 infusion into cerebrospinal fluid did not protect hippocampal neurons from ischemic damage. These results suggest that IL-2 and IL-2Rbeta show malfunction from 3 h after ischemia, and exogenous IL-2 does not protect ischemic neuronal damage.
Hwang
In Koo
IK
Department of Anatomy, College of Medicine, Hallym University, Chunchon 200-702, South Korea.
Yoo
Ki-Yeon
KY
Department of Anatomy, College of Medicine, Hallym University, Chunchon 200-702, South Korea.
Kim
Dae Won
DW
Department of Biomedical Sciences and Research Institute for Bioscience and Biotechnology, Hallym University, Chunchon 200-702, South Korea.
Lee
Hak-Ju
HJ
Division of Wood Chemistry and Microbiology, Korea Forest Research Institute, Dongdaemun-gu, Seoul 130-712, South Korea.
Kang
Ha-Young
HY
Division of Wood Chemistry and Microbiology, Korea Forest Research Institute, Dongdaemun-gu, Seoul 130-712, South Korea.
Lee
Hyeon-Yong
HY
School of Biotechnology and Bioengineering, Kangwon National University, Chunchon 200-701, South Korea.
Kang
Tae-Cheon
TC
Department of Anatomy, College of Medicine, Hallym University, Chunchon 200-702, South Korea.
Choi
Soo Young
SY
Department of Biomedical Sciences and Research Institute for Bioscience and Biotechnology, Hallym University, Chunchon 200-702, South Korea.
Kim
Yong-Sun
YS
Ilsong Institute of Life Science, Hallym Academy of Sciences, Hallym University, Ilsong Building, Kwanyang-dong 1605-4, Dongan-gu, Anyang 431-060, South Korea; MRC Research Institute, Hallym University, Chuncheon 200-702, Republic of Korea.
Won
Moo Ho
MH
Department of Anatomy, College of Medicine, Hallym University, Chunchon 200-702, South Korea; MRC Research Institute, Hallym University, Chuncheon 200-702, Republic of Korea. Electronic address: mhwon@hallym.ac.kr.
D000818:Animals; D020520:Brain Infarction / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D002545:Brain Ischemia / Q000276:immunology* / Q000378:metabolism / Q000503:physiopathology; D016923:Cell Death / Q000187:drug effects / Q000276:immunology; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000276:immunology; D004660:Encephalitis / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D005849:Gerbillinae; D006624:Hippocampus / Q000276:immunology* / Q000378:metabolism / Q000503:physiopathology; D007150:Immunohistochemistry; D007276:Injections, Intraventricular; D007376:Interleukin-2 / Q000276:immunology* / Q000378:metabolism / Q000494:pharmacology; D002546:Ischemic Attack, Transient / Q000276:immunology* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D009410:Nerve Degeneration / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D018696:Neuroprotective Agents / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology; D017966:Pyramidal Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000819:agonists / Q000276:immunology* / Q000378:metabolism; D013997:Time Factors; D017211:Treatment Failure
D007376:Interleukin-2; D018696:Neuroprotective Agents; D015375:Receptors, Interleukin-2